The India-EU Pharmaceutical Corridor: USD 4.2 Billion and Growing

India pharmaceutical exports to EU reached approximately USD 4.2 billion in FY2025. The corridor is dominated by APIs from Hyderabad, Ahmedabad, and Mumbai clusters destined for EU drug manufacturers, and generic finished dose formulations entering EU markets through licensed distributors. India supplies approximately 26% of all generic medicines consumed in the UK.

The regulatory gateway: EU pharma market entry is among the most complex in the world. Indian API manufacturers need either a CEP from EDQM or registration of an Active Substance Master File with an EU national authority. Finished dose manufacturers need EU GMP certification and a Marketing Authorisation. The full pathway from investment decision to first EU sale typically takes 3-5 years.

India-EU FTA pharma provisions: The IP chapter is the most contentious element. EU seeks data exclusivity provisions and patent term extensions. India resists data exclusivity as it delays generic entry — contrary to India constitutional health access obligations and Doha Declaration rights. The negotiated outcome will significantly shape the corridor future.

Opportunity sectors: (1) APIs — EU supply chain diversification push post-COVID actively creates Indian API opportunity; (2) Biosimilars — EU biosimilar market growing as biologics patents expire; (3) Contract manufacturing — EU pharma companies outsourcing to India WHO-GMP/EU-GMP certified facilities; (4) Nutraceuticals — EU market EUR 35B+ and growing.